Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Morden

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to S. Kilickap et al, Y. Karakas et al, and I.A. VoutsadakisJames P Morden, Rosalind A Eeles, Judith M Bliss
BMC Medical Research Methodology|January 13, 2011
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation studyJames P Morden, Paul C Lambert, Nicholas Latimer, et al.
Statistical Methods in Medical Research|April 27, 2016
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation studyNicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
The Lancet. Oncology|January 24, 2012
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane StudyJ Sven D Mieog, James P Morden, Judith M Bliss, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 20, 2013
Fatigue during chemoradiotherapy for nasopharyngeal cancer and its relationship to radiation dose distribution in the brainCeri Powell, Ulrike Schick, James P Morden, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 23, 2014
Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendationsNicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 14, 2012
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trialSarah L Gulliford, Aisha B Miah, Sinead Brennan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized TrialRosalind A Eeles, James P Morden, Martin Gore, et al.
Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2016
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward TrialA Murray Brunt, Duncan Wheatley, John Yarnold, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to S. Kilickap et al, Y. Karakas et al, and I.A. VoutsadakisJames P Morden, Rosalind A Eeles, Judith M Bliss
BMC Medical Research Methodology|January 13, 2011
Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation studyJames P Morden, Paul C Lambert, Nicholas Latimer, et al.
Statistical Methods in Medical Research|April 27, 2016
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation studyNicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
The Lancet. Oncology|January 24, 2012
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane StudyJ Sven D Mieog, James P Morden, Judith M Bliss, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 20, 2013
Fatigue during chemoradiotherapy for nasopharyngeal cancer and its relationship to radiation dose distribution in the brainCeri Powell, Ulrike Schick, James P Morden, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 23, 2014
Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendationsNicholas R Latimer, Keith R Abrams, Paul C Lambert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 14, 2012
Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trialSarah L Gulliford, Aisha B Miah, Sinead Brennan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2015
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized TrialRosalind A Eeles, James P Morden, Martin Gore, et al.
Nature Communications|March 3, 2018
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerBen O'Leary, Sarah Hrebien, James P Morden, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2016
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward TrialA Murray Brunt, Duncan Wheatley, John Yarnold, et al.
Pageof 3